Your trusted source for investing success

Tag: treatment

Arimoclomol for NPC receives Rare Pediatric Disease Designation

Orphazyme A/S, a Danish biotech company (ORPHA:CO), with a late-stage, orphan-drug pipeline, today announced that arimoclomol has been granted rare pediatric disease designation by the US Food and Drug Administration (FDA) for the treatment of Niemann-Pick disease Type C.

As quoted in the press release:
NPC is a genetic disease affecting around

BeiGene Announces Pricing of $750 Million Public Offering

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at

Obalon Therapeutics Prices Public Offering of Common Stock

Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced the pricing of an underwritten public offering of 5,454,545 shares of its common stock at a public offering price of $5.50 per share.

As quoted

Albireo to Receive More than $55 Million in Nondilutive Cash Payments

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Japan’s Ministry of Health, Labor and Welfare has approved the new drug application for elobixibat for the treatment of chronic constipation in Japan.

As quoted in the press release:
“The approval of elobixibat in Japan marks the

Noranda Income Fund Provides an Update on Production

Noranda Income Fund (TSX:NIF.UN) (the “Fund”) provides an update to the market on the work towards returning to normal operating capacity following the ratification of the new collective agreement on December 1, 2017.

As quoted in the press release:

All active unionized employees returned to work at the processing facility in December

Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China

Amarin (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics, announced that a clinical trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia has been commenced in Mainland China, or China, by Amarin’s partner, Eddingpharm.

As quoted in the press release:
Similar to the MARINE trial conducted by Amarin, the

Strongbridge Biopharma Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

Strongbridge Biopharma (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has acquired the U.S. and Canadian rights to MACRILEN™ (macimorelin) from Aeterna Zentaris Inc. (NASDAQ:AEZS).

As quoted from the press release:
“We are extremely

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV™

Celsion Corporation Provides Corporate Update and 2018 Outlook

Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a year-end 2017 corporate review and announced clinical progress for two of its development programs: ThermoDox®, a proprietary, heat-activated liposomal encapsulation of doxorubicin, which is in Phase III development for treatment of primary liver cancer; and GEN-1, an IL-12 DNA plasmid

Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes

Caladrius Biosciences (NASDAQ:CLBS) a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces the completion of enrolment in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial of 110 patients to evaluate the safety and efficacy of the Company’s CLBS03 as

H2O Innovation Adds Two New Projects Worth $2.2 Million

H2O Innovation (TSXV:HEO) has announced two additional new water and wastewater projects in the US.

As quoted in the press release:
These new contracts, worth $2.2 M, will bring the Corporation’s project sales backlog to $51.9 M.

The first contract won by the Corporation consists of a 2-train packaged wastewater treatment system using

Clean Tech Market Report - 2018


Find out how the clean energy market will be affected in 2018


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network